Pear Therapeutics to report Q2 2022 financial results on Thursday, August 11, 2022

BOSTON–(BUSINESS THREAD)–Pear Therapeutics, Inc. (the “Company”) (Nasdaq: PEAR), a leader in the development and commercialization of software-based medicines called prescription digital therapeutics (PDT), today announced that it will release its financial results for the second quarter of 2022 after the close of market on Thursday August. 11, 2022. Management will hold its investor conference call and webcast at 4:30 p.m. ET on the same day to discuss the company’s financial and business highlights.

To access the live conference or webcast, participants must register online at To avoid delays, we recommend that participants register fifteen minutes before the scheduled start time.

A replay of the webcast will be available at investors company section web site approximately two hours after the end of the call and will be archived for up to 30 days.

About Pear Therapeutics

Pear Therapeutics, Inc., which trades on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is a leader in the development and commercialization of software-based medicines, called prescription digital therapeutics (PDT). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to deliver better patient outcomes, smarter monitoring and engagement tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop and deliver PDTs to patients and a portfolio of products and product candidates across therapeutic areas, including the first three PDTs with FDA disease treatment claims. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive the breakthrough designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through the FDA’s traditional 510(k) pathway while concurrently being reviewed through the FDA’s software precertification pilot program. the fda For more information, visit Pera a


Source link

You May Also Like

About the Author: Chaz Cutler

My name is Chasity. I love to follow the stock market and financial news!